MediSpectra’s Luma gains PMA approval
This article was originally published in The Gray Sheet
Executive Summary
A cervical imager that works to identify pre-cancerous cells won PMA approval March 16 from FDA, overcoming last May's 9-2 vote against approving the device from the agency's Obstetrics & Gynecology Devices advisory panel based on concerns about the device's high false positive rate (1"The Gray Sheet" May 23, 2005, p. 11). MediSpectra says when used in conjunction with colposcopy, Luma - the first optical imaging device approved as an aid to clinicians examining women with abnormal Pap tests - identifies sites on the cervix that may contain pre-cancerous cells. FDA's approval was based on data from a study of 193 women that showed Luma detected additional cancer precursors missed by colposcopy...
You may also be interested in...
Ob/Gyn Panel Illuminates Luma Trial Design Problem Areas For MediSpectra
MediSpectra should design and perform a new study to address more closely the specific indication in the firm's PMA for the Luma cervical imager, according to FDA's Obstetrics & Gynecology Devices Panel
Prestige Expands UK Eye Care Range In Response To Consumer Demand
A “great consumer response” to TheraTears in the UK leads Prestige Consumer Healthcare to add TheraTears 5-in-1 Irritation and Redness eye drops to the range.
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.